Year archive

Vivesto — 2014 filings

All 70 regulatory filings released by Vivesto (VIVE) in 2014, sourced directly from the official regulator.

70 Filings

2014 Period

2014 filings (70)

Filing	Released	Lang
Nxt2b förlänger sitt lån till Oasmia Capital/Financing Update	2014-12-30	Swedish
Nxt2b extends loan to Oasmia Capital/Financing Update	2014-12-30	English
Oasmia’s Chairman of the Board buys shares Director's Dealing	2014-12-18	English
Oasmias styrelseordförande köper aktier Director's Dealing	2014-12-18	Swedish
Oasmia byter till Mid Cap segmentet på Nasdaq Stockholm Regulatory Filings	2014-12-17	Swedish
Oasmia change to Mid Cap segment at Nasdaq Stockholm Regulatory Filings	2014-12-17	English
Final result of Oasmia’s rights issue Capital/Financing Update	2014-12-12	English
Slutgiltigt utfall i Oasmias företrädesemission Capital/Financing Update	2014-12-12	Swedish
Preliminary result of Oasmia’s rights issue Capital/Financing Update	2014-12-10	English
Preliminärt utfall i Oasmias företrädesemission Share Issue/Capital Change	2014-12-10	Swedish
Prospectus addendum regarding Oasmia Pharmaceutical's rights issue is now available Capital/Financing Update	2014-12-04	English
Offentliggörande av tilläggsprospekt avseende Oasmia Pharmaceuticals företrädesemission Capital/Financing Update	2014-12-04	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report H1 2015	2014-12-04	Swedish
Interim / Quarterly Report 2014 Interim / Quarterly Report Q2 2014	2014-12-04	English
Prospectus, including new financial information, regarding Oasmia Pharmaceutical's rights issue is now available Capital/Financing Update	2014-11-17	English
Offentliggörande av prospekt, innehållande ny finansiell information, för Oasmia Pharmaceuticals företrädesemission Capital/Financing Update	2014-11-17	Swedish
Oasmia Pharmaceutical AB announces a fully committed and underwritten rights issue of approximately SEK 176 million. Share Issue/Capital Change	2014-11-11	English
Oasmia Pharmaceutical AB offentliggör fullt garanterad företrädesemission av aktier om cirka 176 miljoner SEK. Capital/Financing Update	2014-11-11	Swedish
Oasmias onkologiprodukt Paclical demonstrerar en positiv risk/nytta-profil jämfört med standardbehandling i en omfattande klinisk fas III-studie Earnings Release FY 2014	2014-10-21	Swedish
Oasmia’s lead human oncology product Paclical shows a positive risk/benefit profile versus standard treatment in pivotal phase III clinical study Regulatory Filings	2014-10-21	English
Kommuniké från Oasmias årsstämma 2014 AGM Information	2014-10-01	Swedish
Communiqué from Oasmia’s Annual General Meeting 2014 AGM Information	2014-10-01	English
Oasmia erhåller banklån på 40 MSEK Capital/Financing Update	2014-09-30	Swedish
Oasmia receives a new MSEK 40 bank loan Capital/Financing Update	2014-09-30	English
Oasmia considers secondary listing on NASDAQ USA Regulatory Filings	2014-09-12	English
Oasmia överväger sekundärnotering på NASDAQ i USA Regulatory Filings	2014-09-12	Swedish
Interim / Quarterly Report 2014 Interim / Quarterly Report Q1 2014	2014-09-05	Swedish
Interim / Quarterly Report 2014 Interim / Quarterly Report Q2 2014	2014-09-05	English
Correction of notice regarding notice of Annual General Meeting AGM Information	2014-09-01	English
Rättelse av kallelse avseende kallelse till årsstämma AGM Information	2014-09-01	Swedish
Annual Report 2014 Annual Report FY 2014	2014-08-21	Swedish
Annual Report 2014 Annual Report FY 2014	2014-08-21	English
Major Shareholding Notification 2014 Major Shareholding Notification	2014-08-19	English
Major Shareholding Notification 2014 Major Shareholding Notification	2014-08-04	English
Major Shareholding Notification 2014 Major Shareholding Notification	2014-08-01	English
Offentliggörande av förändring i det totala antalet aktier och röster i Oasmia Share Issue/Capital Change	2014-07-31	Swedish
Publication of change in the total number of shares and votes in Oasmia Declaration of Voting Results & Voting Rights Announcements	2014-07-31	English
Oasmia successfully completes private placement of SEK 50 million Share Issue/Capital Change	2014-07-03	English
Oasmia genomför riktad nyemission om 50 miljoner kronor Share Issue/Capital Change	2014-07-03	Swedish
Oasmia offentliggör placering av nya aktier Share Issue/Capital Change	2014-07-02	Swedish
Oasmia announces launch of private placement of new shares Share Issue/Capital Change	2014-07-02	English
Oasmia signs agreement for patented technology XR-17 M&A Activity	2014-06-25	English
Oasmia tecknar avtal för den patenterade teknologin XR-17 Regulatory Filings	2014-06-25	Swedish
Oasmia utökar sitt produktionsavtal med Baxter Regulatory Filings	2014-06-24	Swedish
Oasmia extends its production agreement with Baxter Regulatory Filings	2014-06-24	English
Oasmias ledande humanproduktkandidat Paclical® har framgångsrikt uppfyllt studiemålen i omfattande fas III-studie Regulatory Filings	2014-06-16	Swedish
Oasmia’s Lead Human Product Paclical® Successfully Meets Primary Objective in Pivotal Phase III Clinical Study Earnings Release FY 2014	2014-06-16	English
Audit Report / Information 2014 Audit Report / Information FY 2014	2014-06-05	Swedish
Interim / Quarterly Report 2014 Interim / Quarterly Report FY 2014	2014-06-05	English
Oasmias första läkemedelsprodukt Paccal Vet®-CA1 presenteras vid ACVIM Forum i Nashville 4-7 juni Earnings Release FY 2014	2014-06-02	Swedish
Oasmia’s Lead Product Paccal Vet®-CA1 Presented at the ACVIM Forum in Nashville on June 4 Environmental & Social Information	2014-06-02	English
Oasmia anställer ny finansdirektör Board/Management Information	2014-05-15	Swedish
Oasmia recruits a new CFO Board/Management Information	2014-05-15	English
Oasmias produktionsanläggning godkänd i EU Regulatory Filings	2014-05-14	Swedish
Oasmia’s production facility approved in the EU Regulatory Filings	2014-05-14	English
Offentliggörande av förändring i det totala antalet aktier och röster i Oasmia Share Issue/Capital Change	2014-03-31	Swedish
Publication of change in the total number of shares and votes in Oasmia Share Issue/Capital Change	2014-03-31	English
Oasmia receives a new MSEK 40 bank loan Capital/Financing Update	2014-03-25	English
Oasmia erhåller banklån på 40 MSEK Capital/Financing Update	2014-03-25	Swedish
Oasmia successfully completes private placement of approximately SEK 72 million Share Issue/Capital Change	2014-03-07	English
Oasmia genomför riktad nyemission om cirka 72 miljoner kronor Share Issue/Capital Change	2014-03-07	Swedish
Oasmia announces launch of private placement of new shares Share Issue/Capital Change	2014-03-06	English
Oasmia offentliggör placering av nya aktier Share Issue/Capital Change	2014-03-06	Swedish
Interim / Quarterly Report 2014 Interim / Quarterly Report 9M 2014	2014-03-06	Swedish
Interim / Quarterly Report 2014 Interim / Quarterly Report 9M 2014	2014-03-06	English
Oasmia erhåller villkorat FDA-godkännande för sitt första läkemedel Paccal Vet®-CA1 Regulatory Filings	2014-02-28	Swedish
Oasmia Receives FDA Conditional Approval For Its Lead Product Paccal Vet®-CA1 Regulatory Filings	2014-02-28	English
Oasmia Receives FDA Conditional Approval For Its Lead Product Paccal Vet(r)-CA1 Legal Proceedings Report	2014-02-28	English
Oasmias finansdirektör Weine Nejdemo går i pension Board/Management Information	2014-01-21	Swedish
Oasmia’s Chief Financial Officer Weine Nejdemo retires Board/Management Information	2014-01-21	English

Filings by year

2026 16 filings
2025 23 filings
2024 13 filings
2023 27 filings
2022 59 filings
2021 29 filings
2020 53 filings
2019 224 filings
2018 96 filings
2017 81 filings
2016 76 filings
2015 56 filings
2014 70 filings
2013 38 filings
2012 42 filings
2011 48 filings
2010 41 filings
2009 44 filings
2008 22 filings
2007 10 filings